A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome

Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide was shown to reduce endothelial cell activation in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Caron A., Rosenthal, Allison C., Arnason, Jon, Agarwal, Shirali, Zhang, Peixin, Wu, Wendy, Amber, Vian, Yared, Jean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692301/
https://www.ncbi.nlm.nih.gov/pubmed/37399456
http://dx.doi.org/10.1182/bloodadvances.2023009961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692301/
https://www.ncbi.nlm.nih.gov/pubmed/37399456
http://dx.doi.org/10.1182/bloodadvances.2023009961

Ejemplares similares